Medycyna oparta na dowodach to nie tylko hasło. To codzienna odpowiedzialność, która zaczyna się od odwagi, by z pokorą analizować własne wyniki.
📌 Why Analyzing Our Own Treatment Outcomes MattersRecently, I had a fascinating conversation with one of my patients — one that, I believe, reflects the growing awareness among patients and a question more and more responsible physicians are beginning to ask.
He asked:
“Doctor, nowadays many centers showcase new technologies or treatment tools on social media — which is helpful, of course — but why does no one seem to talk about their actual treatment outcomes? How do they know what works if they don’t analyze their results?”
This question hits the mark.
🎯 The most reputable oncology centers don’t just rely on technologies — they constantly analyze the outcomes of their own work.
They conduct both prospective and retrospective studies, learning from real-life patient data rather than assumptions or intuition.
These insights help improve effectiveness, minimize adverse effects, and refine treatment strategies — not based on belief, but on measurable outcomes.
It is not enough to believe that we’re helping. We must demonstrate it and improve upon it — ideally through peer-reviewed publications, verified by experts in the field.
📊 This is why we are proud to present the latest results from our team.
We now share our third clinical cohort of patients with colorectal liver metastases — this time in the context of induced oligoprogression, i.e., patients initially presenting with widespread metastatic disease who, following systemic therapy, developed progression limited to a small number of liver lesions.
Our focus: the role of CT-guided HDR brachytherapy in this scenario.
📌 Study Summary:
In the largest reported cohort to date, we evaluated CT-guided high-dose-rate brachytherapy (CT-BRT) in patients with colorectal cancer liver metastases undergoing induced oligoprogression (n=75).
Median OS was 17 months, median PFS 10 months, with minimal toxicity (1% Grade 3, none above G3).
Treatment responses included: CR in 8%, PR in 31%, SD in 47%, and PD in 15%.
OS was positively influenced by achieving disease control with a high dose. PFS was affected by the number of metastases and presence of extrahepatic disease (notably abdominal/pelvic lymph nodes).
📎 Manuscript: Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases
👉 Full publication https://www.nature.com/articles/s41598-025-09227-0
— we invite feedback from colleagues and patients alike!
🧠 Final Thought:
📚 Evidence-based medicine is not just a slogan. It is a daily responsibility — and it begins with the humility to analyze our own results.